UK silent heart attack market is estimated to grow considerably at a CAGR of around 6.8% during the forecast period. UK has one of the finest healthcare systems in the EU region which enables it to provide quality healthcare to the individual citizens. According to British Heart Foundation, more than 7 million people are living with one or the other type of heart diseases in UK. Lingering heart diseases put economic burden to the UK government which includes cost of premature deaths, lost productivity, hospital stay and prescriptions which are estimated to be around $50 billion annually. According to the British Heart Foundation, 0.17 million heart attacks occur every year in UK. In which 0.11 million men and 0.06 million women lose their life annually in UK due to heart attack each year.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/uk-silent-heart-attack-market
UK silent heart attack market is segmented into diagnosis, treatment, and end-user. Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest x-ray, computed tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics and ambulatory surgical centers (ASCs). Significant availability of hospitals coupled with the presence of skilled professionals with different specialties in hospitals is contributing to the treatment if silent heart attack in hospitals and clinics. Therefore, hospitals and clinics are mainly preferred for the treatment of CVD conditions.
The companies which are contributing to the growth of the UK silent heart attack market include AstraZeneca PLC, Bayer AG, Siemens AG, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim GmbH, and GlaxoSmithKline Plc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
UK Silent Heart Attack Market Segmentation
By Diagnosis
- Electrocardiography (ECG)
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT Scan)
- Echocardiography
- Others (Blood Test)
By Treatment
- Medication
- Surgery
- Angioplasty
- Bypass Surgery
- Heart Transplant
By End-Users
- Hospital & Clinics
- Ambulatory Surgical Centers
A full report of UK Silent heart attack Market available @ https://www.omrglobal.com/industry-reports/uk-silent-heart-attack-market
Company Profiles
- Astellas Pharma Inc.
- AstraZeneca PLC
- Bayer AG
- Boehringer Ingelheim GmbH
- Boston Scientific Corp.
- Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Medtronic PLC
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Siemens AG
- Takeda Pharmaceutical Co. Ltd.
